Equity · Healthcare
LGND
NASDAQLigand Pharmaceuticals (LGND)
The line runs 288 USD on 13 August through 289 USD on 10 September, on a scale from 270 to 300. Days the market did not trade hold the previous close, flat.
- Market cap
- 5.8B USD
- P/E (TTM)
- 113.8
- Revenue, year to Dec 2025
- 268.1M USD
- EPS, diluted, year to Dec 2025
- 6.13 USD
- 52-week range
- 165 USD – 323 USD
- Avg volume
- 28.0K
as of Sep 10, 2026
Have Ligand Pharmaceuticals (LGND) insiders bought or sold shares recently?
In the 90 days to 12 Nov 2026, Ligand Pharmaceuticals insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Apr 2026, show no open-market purchase.
Form 4, 90 days to 12 Nov 2026, newest reported trade 4 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | Aryeh JasonDirector | Sell | 282 | 90K USD |
| 02 Nov 2026 | Aryeh JasonDirector | Sell | 700 | 224K USD |
| 02 Nov 2026 | Reardon AndrewCLO & Secretary | Sell | 5,000 | 1.6M USD |
| 30 Oct 2026 | Aryeh JasonDirector | Sell | 1,411 | 452K USD |
| 02 Oct 2026 | Reardon AndrewCLO & Secretary | Sell | 5,000 | 1.5M USD |
| 10 Sep 2026 | Zimmermann MartineDirector | Sell | 1,200 | 342K USD |
| 03 Sep 2026 | Reardon AndrewCLO & Secretary | Sell | 5,000 | 1.4M USD |
| Sold | 7 open-market sales | 18,593 | $5.63M |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Reardon AndrewCLO & Secretary | Option exercise | 5,000 | 261K USD |
| 02 Oct 2026 | Reardon AndrewCLO & Secretary | Option exercise | 340 | 18K USD |
| 22 Sep 2026 | Zimmermann MartineDirector | Tax withheld | 115 | 34K USD |
Which funds hold Ligand Pharmaceuticals (LGND)?
1 of the 45 institutional funds we track reported a Ligand Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 40.2M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 128,643 | 40.2M USD | +5.9% |
Have members of Congress traded Ligand Pharmaceuticals (LGND)?
The most recent congressional trade disclosed in Ligand Pharmaceuticals is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 15 Jan 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 15 Jan 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 29 days |
What has been filed or recorded for Ligand Pharmaceuticals (LGND)?
The filings we hold for Ligand Pharmaceuticals, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 02 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 43 shares | 13K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 156 shares | 48K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.43 USD | |
| 30 Sep 2026 | Financials | Total assets | 2.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 961.8M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 2.22 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.67 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 6.13 USD | |
| 31 Dec 2025 | Financials | Revenue | 268.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 124.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 6.13 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 5.68 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.24 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −2.21 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.22 USD |
What do people ask about Ligand Pharmaceuticals (LGND)?
What did Ligand Pharmaceuticals shares close at?289.00
Ligand Pharmaceuticals closed at 289.00 USD on 10 Sep 2026, up 0.35% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Ligand Pharmaceuticals’ market cap?5.8B
Ligand Pharmaceuticals is worth 5.8B USD by market value as of 10 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Ligand Pharmaceuticals’ P/E ratio?113.8
Ligand Pharmaceuticals has a price-to-earnings ratio of 113.8, as of 10 Sep 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Ligand Pharmaceuticals’ revenue?268.1M
Ligand Pharmaceuticals reported revenue of 268.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Ligand Pharmaceuticals insiders bought or sold shares recently?7 sales
In the 90 days to 12 Nov 2026, Ligand Pharmaceuticals insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Apr 2026, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Ligand Pharmaceuticals?1 of 45
1 of the 45 funds we track reported a Ligand Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Ligand Pharmaceuticals?1 trade
Yes. 1 trade in Ligand Pharmaceuticals appears in the congressional disclosures we hold: a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 15 Jan 2026, filed 13 Feb 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Ligand Pharmaceuticals last report earnings?−1.43
Ligand Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.43 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Gilbert Ray Cisneros, Jr.: United States Department of Defense, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings